GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:15 2026-04-13 am EDT			5-day change	1st Jan Change
2,170.00 ^GBX	-0.28%		+3.53%	+18.94%

12:16pm	European Stocks Fall in Monday Trading After US-Iran Peace Talks Collapse	MT
08:58am	Earnings Season in Trump's Shadow

GSK : Barclays reiterates its Sell rating

Published on 03/12/2026 at 05:43 am EDT

MarketScreener with dpa-AFX Analyser

GSK PLC

-0.28%

Barclays's analyst James Gordon maintains his Sell rating on the stock. The target price remains set at GBX 1900.

Latest news about GSK plc

12:16pm	European Stocks Fall in Monday Trading After US-Iran Peace Talks Collapse	MT
08:58am	Earnings Season in Trump's Shadow
05:51am	Bioversys Ag Publishes Pre-Clinical Data of Alpe Drug Combination in Nature Communications	CI
05:20am	GSK : JP Morgan maintains a Sell rating	ZD
05:19am	GSK : Jefferies gives a Buy rating	ZD
05:06am	GSK Reports Phase I Trial Data for Mocertatug Rezetecan in Gynaecological Cancers	MT
04:40am	Bernstein cuts Wizz Air and easyJet	AN
04:20am	GSK : Goldman Sachs remains Neutral	ZD
02:51am	European shares poised to open lower as Middle East talks fail	RE
02:26am	Washington raises the stakes
02:01am	GSK posts encouraging data for endometrial and ovarian cancer drug	AN
01:31am	UK Stocks-Factors to watch on April 13	RE
11:18pm	GSK Logs Positive Data in Gynecological Cancers Drug Trial	MT
08:20pm	PRESS DIGEST-Financial Times - April 13	RE
Apr. 12	GSK sees blockbuster potential in targeted cancer therapy after promising early data	RE

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

66,841

Sector

Pharmaceuticals

More about the company